

References

S-118

1. Kubal C, Mangus R, Saxena R, et al. Prospective monitoring of donor-specific anti-HLA antibodies after intestine/multivisceral transplantation: Significance of Dde Nnovo antibodies. *Transplantation*. 2015; 99(8):e49-56.
2. Wu GS, Cruz RJ, Jr, Cai JC. Acute antibody-mediated rejection after intestinal transplantation. *World J Transplant*. 2016;6(4):719-728.
3. Nagai, et al. Cytomegalovirus Infection after intestinal/multivisceral transplantation: A single-center experience with 210 cases. *Transplantation*. 2016;100(2):451-460.
4. Khan FA, Selvaggi G: Overview of intestinal and multivisceral transplantation. Brown R. UpToDate. Waltham, MA: UpToDate Inc.
5. United Network for Organ Sharing (UNOS). OPTN policies, procedures implemented to support HOPE Act. 2015. Accessed April 8, 2019.
6. Dore M, Junco PT, Andres AM, Sánchez-Galán A, Amesty MV, et al. Surgical rehabilitation techniques in children with poor prognosis short bowel syndrome. *Eur J Pediatr Surg*. 2016;26(1):112-116.
7. Rutter CS, Amin I, Russell NK, Sharkey LM, Butler AJ, et al. Adult intestinal and multivisceral transplantation: experience from a single center in the United Kingdom. *Transplant Proc*. 2016;48(2):468-472.
8. Lacaille F, Irtan S, Dupic L, Talbotec C, Lesage F, et al. Twenty-eight years of intestinal transplantation in Paris: Experience of the oldest European center. *Transpl Int*. 2017;30(2):178-186.
9. Ekser B, Kubal CA, Fridell JA, Mangus RS. Comparable outcomes in intestinal retransplantation: Single-center cohort study. *Clin Transplant*. 2018; 32(7):e13290.
10. Organ Procurement and Transplantation Network (OPTN). Organ Procurement and Transplantation Network Policies. 2020.
11. Levitsky J, Formica RN, Bloom RD, et al. The American Society of Transplantation consensus conference on the use of Hepatitis C viremic donors in solid organ transplantation. *Am J Transplant*. 2017; 17:2790-2802.
12. Bharadwaj S, Tandon P, Gohel TD, et al. Current status of intestinal and multivisceral transplantation. *Gastroenterol Rep (Oxf)*. 2017;5(1):20-28.
13. Loo L, Vrakas G, Reddy S, et al. Intestinal transplantation: A review. *Curr Opin Gastroenterol*. 2017;33(3):203-211.
14. Timpone JG, Yimen M, Cox S, et al. Resistant cytomegalovirus in intestinal and multivisceral transplant recipients. *Transpl Infect Dis*. 2016;18(2):202-209.

15. Cromvik J, Varkey J, Herlenius G, et al. Graft-versus-host disease after intestinal or multivisceral transplantation: A Scandinavian single-center experience. *Transplant Proc.* 2016;48(1):185-190.
16. Garcia Aroz S, Tzvetanov I, Hetterman EA, et al. Long-term outcomes of living-related small intestinal transplantation in children: A single-center experience. *Pediatr Transplant.* 2017;21(4).
17. Luckett k, Kaiser TE, Bari K, et al. Use of hepatitis C virus antibody-positive donor livers in hepatitis C nonviremic liver transplant recipients. *J AM Coll Surg* 2019;228(4):560-567.
18. Saberi B, Hamilton JP, Durand CM, et al. Utilization of hepatitis C virus RNA-positivedonor liver for transplant to hepatitis C virus RNA-negative recipient. *Liver Transpl.* 2018;24(1):140-143.
19. Campos-Varela I, Agudelo EZ, Sarkar M, et al. Use of hepatitis C virus(HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient. *Transpl Infect Dis.* 2018;20(1).
20. Kwong AJ, Wall A, Melcher M, et al. Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors. *Am J Transplant.* 2019;19(5): 1380-1387.
21. InterQual® Level of Care Criteria 2019. Acute Care Adult. Change Healthcare, LLC.